Drug resistance of enzalutamide in CRPC.

Drug resistance of enzalutamide in CRPC. Curr Drug Targets. 2017 Apr 17;: Authors: Chen X, Lu J, Xia L, Li G Abstract Enzalutamide (MDV3100, XTANDI ) is a second generation androgen receptor inhibitor that is designed for the treatment of castration-resistant prostate cancer (CRPC) and has prolonged survival time. Although Enzalutamide was also associated with such significant benefits, The majority of treated patients, innate or acquired resistance invariably arises, but the mechanisms of mdv3100 resistance have not yet been clearly clarified. Nevertheless, because the better knowledge of the genetic landscape of MDV3100 is under way, resistance to MDV3100 could be basically divided in two distinct pathways, either dependent or independent of the androgen receptor activity. Androgen receptor (AR) axis is the most important pathway for prostate cancer cells and it is still currently regarded as a critical resistant mechanism. The purpose of this review is to summarize the main data available on the mechanisms of resistance to mdv3100. Understanding how the resistance is aroused may have clinical implications in underlying the usefulness of prognostic and predictive biomarkers in daily practice and improving the strategies. PMID: 28413979 [PubMed - as supplied by publisher]
Source: Current Drug Targets - Category: Drugs & Pharmacology Authors: Tags: Curr Drug Targets Source Type: research